Every 10-Q that QuidelOrtho Corporation (QDEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QDEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QDEL filings page.
QuidelOrtho Corporation reported weaker Q1 2026 results, with an 11% revenue decline to $619.8 million and a much larger net loss of $91.8 million, or $1.35 per share. Revenue fell mainly in U.S. respiratory testing and Donor Screening, and from terminating a Joint Business with Grifols.
Cost of sales rose to 57.4% of revenue, and higher selling, marketing and administrative expenses and interest costs contributed to an operating loss of $31.8 million and loss before income taxes of $79.5 million. Operating cash flow swung from a $65.6 million inflow in Q1 2025 to a $33.0 million outflow.
The company ended the quarter with $140.4 million in cash and $2.69 billion of total borrowings, and remained in compliance with credit covenants. It is executing a multi‑year Optimization Plan targeting about $50 million of net savings by 2027 and is winding down its U.S. donor screening portfolio. After quarter‑end, QuidelOrtho agreed to acquire LEX Diagnostics for about $100 million in cash plus up to $35 million in earn‑outs.
QuidelOrtho Corporation reported a quarterly net loss of $733.0 million, largely due to a non-cash goodwill impairment of $700.7 million that eliminated all remaining goodwill. Total revenues were $699.9 million, down from $727.1 million a year ago, as lower Point of Care sales offset growth in Labs and Immunohematology.
Operating results reflected $39.6 million of restructuring, $47.7 million of intangible amortization, and $46.1 million in net interest expense. Year-to-date, the company recorded a net loss of $1,001.1 million and used $26.7 million in operating cash.
QuidelOrtho refinanced its capital structure on August 21, 2025, entering a new Credit Agreement with a $1.15B Term Loan A, $1.45B Term Loan B, and a $700.0M revolver; it repaid prior facilities and ended the quarter with $2.66B in total borrowings and $98.1 million in cash. Segment revenue was led by Labs $373.8M and Point of Care $164.6M. A final judgment related to a supplier dispute required payment of $10.8 million.